Inherent Biosciences, Inc.
PrivateLast Round
Accelerator
Jun 2, 2025
Total Funding Raised
$4.01M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Inherent Biosciences, Inc. operates in Healthcare & Life Sciences and is based in Salt Lake City, Utah. Its latest recorded funding round was an Accelerator round in June 2025.
Inherent Biosciences, Inc. is a biotechnology company that develops epigenetic medicine platforms and diagnostic tools for complex diseases, with a primary focus on reproductive health.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical AI, Precision Medicine
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inherent Biosciences, Inc. Comparables
Compare Inherent Biosciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genomic Prediction | 74% | |
| Fellow | 70% | |
| Luminary Life Sciences | 70% |
For institutional investors. Book with your work email.
Inherent Biosciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jun 2, 2025 | ||||
| VC Round | Dec 12, 2023 | ||||
| Grant | Aug 17, 2023 | ||||
| Grant | May 31, 2023 | ||||
| Series A | Sep 7, 2022 | ||||
Grant | Apr 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inherent Biosciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Portfolia | Series A |
| Utah Innovation Fund | VC Round |
| Propel Bio Partners | Series A |
| HealthTech Investors | Accelerator |
| Rhythm Venture Capital | Seed |
| Park City Angels | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 80% MoM.
- Feb 17, 2021
Led by National Science Foundation with participation from Kickstart.
For institutional investors. Book with your work email.
Inherent Biosciences, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inherent Biosciences, Inc.'s valuation, stock price, and market status.
Is Inherent Biosciences, Inc. a public or private company?
Inherent Biosciences, Inc. is a private company.
What is the current stock price of Inherent Biosciences, Inc.?
Inherent Biosciences, Inc. is a private company, so its shares have no public market price. Caplight tracks Inherent Biosciences, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inherent Biosciences, Inc. worth (valuation)?
Valuation information for Inherent Biosciences, Inc. is not publicly available.
Can I buy Inherent Biosciences, Inc. stock?
Inherent Biosciences, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inherent Biosciences, Inc.'s last funding round?
Inherent Biosciences, Inc.'s most recent funding round was Accelerator on June 2, 2025.
Who are the main investors in Inherent Biosciences, Inc.?
Key investors in Inherent Biosciences, Inc. include NIH RADx, Propel Bio Partners, HealthTech Investors, National Science Foundation.
Will Inherent Biosciences, Inc. IPO soon?
No public IPO plans have been announced for Inherent Biosciences, Inc..
How can I track Inherent Biosciences, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Inherent Biosciences, Inc.'s shares on secondary markets.